Clinical Trial of Comparing DA-5222 Single-administration and Co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in Healthy Adult Subjects

Launched by DONG-A ST CO., LTD. · May 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called DA-5222 and its different forms (DA-5222-R1, DA-5222-R2, and DA-5222-R3) to see how they are absorbed and processed by the body, as well as how safe they are. The trial will involve healthy adult volunteers who will either receive a single dose of DA-5222 or a combination of the different forms. The goal is to gather important information about how these medications work in people who are generally healthy.

To be eligible for this trial, participants must be healthy adults aged 18 to 39 with a body mass index (BMI) between 18 and 30, and meet certain weight requirements (at least 50 kg for males and 45 kg for females). Participants will need to sign a consent form to show they understand the study. However, individuals with significant medical issues, a history of drug addiction, or allergies to medications will not be able to participate. Those who join can expect to have their health monitored closely during the study to ensure safety and gather data on how the medication affects them. The trial is currently not recruiting participants, but it aims to provide valuable insights once it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy volunteers
• • BMI between 18 and 30 kg/m2
• • Body weight: Male≥50kg, Female≥45kg
• • Subjects who have signed an informed consent themselves after receiving detailed explanation about clinical study
• Exclusion Criteria:
• • Subjects with clinically significant medical history
• • Subjects with history of drug abuse or addicted
• • Subjects with allergy or drug hypersensitivity